More on SLN
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $11.95 |
|
|||
| Open | $16.70 | ||||
| 52 Wk High | $0.27 | ||||
| 52 Wk Low | $0.18 | ||||
| Day High | $17.58 | ||||
| Day Low | $14.62 | ||||
| P/E | N/A | ||||
| EPS | $-0.44 | ||||
| Volume | 16,207,536 | ||||
- Silence Therapeutics launches $150 million ADS public offering
- Silence Therapeutics Announces Proposed Public Offering of $150 Million of American Depositary Shares
- The Catalysts are Back: Socket Mobile Breaks Out while Biotechs Race Toward Major Milestones
- Silence Therapeutics plc (SLN) Tops Q2 EPS by 5c
- Silence Therapeutics' divesiran meets Phase 2 endpoints in blood cancer trial
- Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile
- Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results
- Silence Therapeutics to discuss Phase 2 divesiran trial results
- Silence Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera
- Form 8-K/A Silence Therapeutics For: Jul 10
Entities mentioned with SLN
- FDA | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- 13G | View Related Stories »
- Earnings | View Related Stories »
- H.C. Wainwright | View Related Stories »
- 13D | View Related Stories »
- Show More...
